If youve been following medications like Ozempic , Wegovy , or Zepbound (tirzepatide) , you know they belong to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
You will read about the dangers of insulin resistance and excess insulin, and how some of the drugs that mainstream medicine uses to treat diabetes increase insulin levels without regard to ambient glucose levels, potentially contributing to problems in the long term
data, filling a gap left by research focused on diabetic populations or using less comprehensive samples
It is no longer useful to think of obesity as a single, monolithic market
eCAM (published in advance)
The main trade-offs are hidden pricing for non-core meds and a cancellation process that could be clearer